bluebird raises $60 million in series D

Gene therapy company bluebird bio Inc. (Cambridge, Mass.) raised $60 million in a series D round. New investors Deerfield Partners; RA Capital; Ramius Capital Group; Shire plc (LSE:SHP; NASDAQ:SHPGY); and two undisclosed public investment funds participated, along with existing investors Arch Venture Partners; Third Rock Ventures; TVM Capital; and Forbion Capital Partners. Cowen was an advisor. ...